Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to fund research and treatments for polycystic kidney disease cures.
The problem
Polycystic kidney disease affects thousands of Americans, causing kidney failure and requiring dialysis or transplants. Current treatments manage symptoms but do not cure the disease.
The proposal
The bill allocates federal funding for research into PKD causes, treatments, and potential cures. It supports clinical trials and development of new therapeutic approaches.
The impact
PKD patients, researchers, and medical institutions gain resources. Taxpayers fund the research. Healthcare system may see reduced kidney failure complications long-term.
Increased funding accelerates research into better treatments and potential cures for PKD. This could improve quality of life for patients and reduce the need for dialysis or transplants. Scientific breakthroughs benefit the broader medical community.
Finding cures or better treatments could lower long-term healthcare expenses by reducing dialysis, transplants, and complications. Prevention and early intervention are typically cheaper than managing advanced disease.
Federal funding creates research positions and supports institutions conducting PKD studies. This stimulates economic activity in the scientific and medical research sectors.
PKD affects a smaller population, making private investment limited. Government funding fills this gap and ensures research continues on diseases affecting fewer patients.
The bill requires taxpayer funding for research that may take years to show results. The total cost and budget impact are unclear without specific appropriation amounts.
Government-funded research does not guarantee successful cures or treatments. Money spent may not lead to practical medical breakthroughs or FDA-approved drugs.
Focusing on PKD means other kidney diseases or serious conditions receive less attention and funding. Resources are finite, and prioritizing one disease affects others.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.